Systane Ultra Versus Maxidex Versus Saline

This study has been completed.
Sponsor:
Collaborator:
Alcon Research
Information provided by (Responsible Party):
Penny Asbell, Mount Sinai School of Medicine
ClinicalTrials.gov Identifier:
NCT01775540
First received: December 7, 2012
Last updated: January 22, 2013
Last verified: January 2013
  Purpose

This study was to evaluate the healing action on the eye surface of the artificial tear Systane® ULTRA as compared to two other eyedrops: Maxidex and Saline solution. Dry eye disease leads to inflammation of the eye surface and treating dry eyes with artificial tears may lead to reduction in this inflammation and improvement of symptoms and signs.


Condition Intervention
Dry Eye Disease
Drug: Systane Ultra
Drug: Saline solution
Drug: Maxidex

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Study to Evaluate the Ocular Surface Healing Action of the Artificial Tear Systane ULTRA Using Both Positive (Maxidex) and Negative (Saline Solution) Controls

Resource links provided by NLM:


Further study details as provided by Mount Sinai School of Medicine:

Primary Outcome Measures:
  • OSDI score [ Time Frame: at Baseline ] [ Designated as safety issue: No ]
    questionnaire pertaining to dry eye symptoms answered by patients

  • OSDI score [ Time Frame: visit 2 (at 2 weeks) ] [ Designated as safety issue: No ]
    questionnaire pertaining to dry eye symptoms answered by patients

  • OSDI score [ Time Frame: at visit 3 (at 4 weeks) ] [ Designated as safety issue: No ]
    questionnaire pertaining to dry eye symptoms answered by patients


Secondary Outcome Measures:
  • Tear Film break up time [ Time Frame: at Baseline ] [ Designated as safety issue: No ]
    Time taken for the first dry spot to appear in the tear film

  • Tear Film break up time [ Time Frame: at visit 2 (at 2 weeks) ] [ Designated as safety issue: No ]
    Time taken for the first dry spot to appear in the tear film

  • Tear Film break up time [ Time Frame: at visit 3 (at 4 weeks) ] [ Designated as safety issue: No ]
    Time taken for the first dry spot to appear in the tear film

  • Corneal Staining [ Time Frame: at Baseline ] [ Designated as safety issue: No ]
    Grading of fluorescein staining of the cornea using a slit lamp and NEI grading scale

  • Corneal Staining [ Time Frame: at visit 2 (at 2 weeks) ] [ Designated as safety issue: No ]
    Grading of fluorescein staining of the cornea using a slit lamp and NEI grading scale

  • Corneal Staining [ Time Frame: at visit 3 (at 4 weeks) ] [ Designated as safety issue: No ]
    Grading of fluorescein staining of the cornea using a slit lamp and NEI grading scale

  • Conjunctival Staining [ Time Frame: at Baseline ] [ Designated as safety issue: No ]
    Grading of Lissamine green staining of the conjunctiva using a slit lamp and NEI grading scale

  • Conjunctival Staining [ Time Frame: at visit 2 (at 2 weeks) ] [ Designated as safety issue: No ]
    Grading of Lissamine green staining of the conjunctiva using a slit lamp and NEI grading scale

  • Conjunctival Staining [ Time Frame: at visit 3 (at 4 weeks) ] [ Designated as safety issue: No ]
    Grading of Lissamine green staining of the conjunctiva using a slit lamp and NEI grading scale

  • Best corrected visual acuity [ Time Frame: at Baseline ] [ Designated as safety issue: No ]
    BSCVA using ETDRS charts

  • Best corrected visual acuity [ Time Frame: at visit 2 (at 2 weeks) ] [ Designated as safety issue: No ]
    BSCVA using ETDRS charts

  • Best corrected visual acuity [ Time Frame: at visit 3 (at 4 weeks) ] [ Designated as safety issue: No ]
    BSCVA using ETDRS charts

  • Tear Cytokines [ Time Frame: At baseline ] [ Designated as safety issue: No ]
    Tear samples collected from both eyes using microcapillary tube. Samples analysed for inflammatory cytokines using Luminex bioassays

  • Tear Cytokines [ Time Frame: At visit 3 (at 4 weeks) ] [ Designated as safety issue: No ]
    Tear samples collected from both eyes using microcapillary tube. Samples analysed for inflammatory cytokines using Luminex bioassays

  • mRNA for HLA-DR [ Time Frame: At baseline ] [ Designated as safety issue: No ]
    Cell samples collected via impression cytology and analysed for mRNA expression via flowcytometer

  • mRNA for HLA-DR [ Time Frame: At visit 3 (at 4 weeks) ] [ Designated as safety issue: No ]
    Cell samples collected via impression cytology and analysed for mRNA expression via flowcytometer

  • HLA-DR expression [ Time Frame: At baseline ] [ Designated as safety issue: No ]
    Cell samples collected via impression cytology and analysed for HLA-DR expression via flowcytometer

  • HLA-DR expression [ Time Frame: At visit 3 (at 4 weeks) ] [ Designated as safety issue: No ]
    Cell samples collected via impression cytology and analysed for HLA-DR expression via flowcytometer

  • IDEEL questionnaire [ Time Frame: At baseline ] [ Designated as safety issue: No ]
    questionnaire pertaining to dry eye symptoms, quality of life, and treatment answered by patients

  • IDEEL questionnaire [ Time Frame: At visit 2 (at 2 weeks) ] [ Designated as safety issue: No ]
    questionnaire pertaining to dry eye symptoms, quality of life, and treatment answered by patients

  • IDEEL questionnaire [ Time Frame: At visit 3 (at 4 weeks) ] [ Designated as safety issue: No ]
    questionnaire pertaining to dry eye symptoms, quality of life, and treatment answered by patients


Enrollment: 36
Study Start Date: May 2012
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Systane Ultra
Artificial tear Eyedrop, 1 drop used four times a day (QID) for 4 weeks
Drug: Systane Ultra
Artificial tear Eyedrop, 1 drop used QID for 4 weeks
Other Name: Artificial Tears
Placebo Comparator: Saline solution
Saline solution Eyedrop, 1 drop used QID for 4 weeks
Drug: Saline solution
Saline solution,1 drop used QID for 4 weeks
Active Comparator: Maxidex
Steroid eyedrop, 1 drop QID for 4 weeks
Drug: Maxidex
Eyedrop-1 drop QID for 4 weeks
Other Name: Dexamethasone 0.1% eyedrop

Detailed Description:

For all patients who present to the office with a history of dry eyes:

  1. Consent forms will be obtained from every patient. Informed consent will be discussed with the patient in detail. Every topic will be addressed separately. All risks, benefits, and alternatives will be discussed. Patient will be allowed to ask questions, and all questions will be answered. The assessment will be made after that conversation, whether or not the patient understood the consent as described above. Each subject will be allowed as much time as needed to review and sign the consent forms.
  2. All patients will be asked to fill out the Ocular Surface Discomfort Index (OSDI) questionnaire to ensure they meet the inclusion criteria. If patients score meets eligibility requirements a general and ocular history will be taken. (Time: 10 min)
  3. A pregnancy test will be given to all female subjects of child bearing age. A standard eye exam will be performed to rule out any other ocular pathology besides refractive error. This allows for confirmation that all study subjects have dry eye disease. Topical fluorescein and lissamine dye will be used to record staining on the cornea and conjunctiva of subjects as well as the tear film break-up time (TFBUT). Both of these dyes are used as standard-of-care in eye exams around the country. TFBUT will first be determined through application of sodium fluorescein onto the eye using DET strip. Following triplicate evaluation of TFBUT in each eye, ocular staining will be determined with liquid fluorescein and lissamine dyes administered in liquid form. (Time 15 min).
  4. Patients will be given Alcon questionnaires to fill out, inquiring about past treatments, daily symptoms and distress associated with their dry eye disease. (Time:15 minutes) This also serves as a waiting period for some of the dye to wash out.
  5. Using a graduated disposable 5 µl microcapillary tube (Wiretol-Micropipettes, Drummond Scientific Co., Broomall, PA, USA) up to 5 µl of tears / eye will be collected from the inferior temporal tear meniscus of each participant, without corneal anesthesia, taking care to ensure that the lid margin and corneal surface were not touched. A maximum of 5 minutes will be allowed per eye for collection of minimal 5 uL of tear. Tears will be immediately dispensed into pre-labeled Eppendorf tubes and placed on dry ice until transferred to -80oC for storage. (Time: 10 minutes)
  6. A technique known as Impression Cytology (IC) will be used to isolate epithelial cells from the conjunctiva. Anesthetic drops will be administered to each eye before the procedure. Blunted forceps are used to gently press a piece of filter paper against the patient's conjunctiva. The paper is gently lifted off, and sent to the Mount Sinai Laboratory for analyses. (Estimated collection time: 15 minutes). A total of 6 pieces per patient (3 pieces per eye) will be collected on each scheduled visit. For HLA-DR analysis, 2 pieces from each eye will be held at room temperature in a vial containing fixative until assay. The remaining 1 piece from each eye will be pooled together in one vial for RT-PCR assays in the following order: (1) immediately merged into a pre-labeled Eppendorf tube with 600 µL of TriZol Reagent; (2) Vortex for 30 seconds; (3) sealed with Saran Wrap; (4) transfer to -80C for storage until assay.
  7. Measurement of Intraocular pressure using Tonopen.
  8. As a part of the substudy we intend to treat patients with Systane ULTRA®, Maxidex, (both of which are FDA approved ophthalmic solutions), or the saline solution placebo. Subjects will be assigned to one of the three groups as per randomization sequence and the corresponding eye drop will be dispensed.
  9. The patient's response to treatment will be assessed after approximately 4 weeks (+/- 5 days) using the same diagnostic tests in order to assess the sensitivity of these diagnostic tests to detect the response to medical treatment of dry eye disease. In addition to baseline and 4 week visits, safety evaluations will be performed at a 2 week (+/- 5 days) visit. All the procedures done during the baseline visit will be repeated except pregnancy test, tear collection and impression cytology.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • A score of at least 15 on the Ocular Surface Discomfort Index (OSDI) symptom questionnaire.
  • Moderate vital staining, fluorescein (for corneal evaluation, 3-15 on the NEI scale) OR lissamine (for conjunctival evaluation, score of 2-6; temporal and nasal areas, each graded 0-3).
  • Willingness to use study drugs 4 times per day in both eyes.
  • Willingness to discontinue use of other artificial tear products.
  • Patient must provide written informed consent
  • Patient must understand the scope of the study including completion of worksheet and be willing to follow instructions and return for all required study visits
  • An intraocular pressure less than or equal to 22 mmHg in both eyes

Exclusion Criteria:

  • Contact Lens wearers
  • Pregnant and/or lactating women
  • Those with moderate to severe Meibomian Gland Disease i.e. plugging of 3 or more glands and/or pasty secretion from 3 or more glands or presence of obstructed glands out of a total of 10 glands evaluated in the central portion of the lower lid.
  • Uncontrolled systemic or ocular disease
  • Dry eye due to seasonal allergic conjunctivitis, contact lens related conjunctivitis or other acute or seasonal diagnosis.
  • Are monocular and/or legally blind
  • Had ocular surgery or trauma within last six months
  • Participation in an ophthalmic drug or device research study within 30 days prior to entry in this study
  • Current use of any eye drops other than artificial tears
  • Use of Restasis within three months prior to entry in this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01775540

Locations
United States, New York
Mount Sinai School of Medicine
New York, New York, United States, 10029
Sponsors and Collaborators
Mount Sinai School of Medicine
Alcon Research
Investigators
Principal Investigator: Penny Asbell, MD, MBA, FACS Mount Sinai School of Medicine
  More Information

No publications provided

Responsible Party: Penny Asbell, Professor, Mount Sinai School of Medicine
ClinicalTrials.gov Identifier: NCT01775540     History of Changes
Other Study ID Numbers: GCO 11-1230
Study First Received: December 7, 2012
Last Updated: January 22, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Mount Sinai School of Medicine:
Dry eye
Artificial tears
Ocular surface inflammation

Additional relevant MeSH terms:
Eye Diseases
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Ophthalmic Solutions
Pharmaceutical Solutions
Anti-Inflammatory Agents
Antiemetics
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Autonomic Agents
Central Nervous System Agents
Enzyme Inhibitors
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on October 29, 2014